Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Financings

Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement

By The Northwire Desk — AI Analysis Dec 19, 2025 · 08:45 PRN · 10.59 PROFOUND MEDICAL CORP.
PRN · Price

Executive Summary

  • Profound Medical Corp. announced a registered direct offering of 5,142,857 common shares at $7.00 per share, targeting gross proceeds of up to $36 million (approximately $40 million including the subsequent private placement).
  • A concurrent Canadian private placement of up to 571,428 common shares at $7.00 per share is planned, expected to raise up to $4 million, with a four‑month plus one day lock‑up period for purchasers.
  • Net proceeds are earmarked for expansion of sales and marketing, working capital, R&D, strategic transactions, and general corporate purposes.

Key Details

  • Offering Structure:
  • Registered direct offering – equity only, no warrant coverage.
  • Led by healthcare‑focused investors and existing shareholders.

  • Expected closing: on or about Monday, Dec 22 2025 (subject to customary conditions).

  • Share Quantities & Pricing:

  • Direct offering: 5,142,857 shares @ $7.00/share → gross proceeds ≈ $36 M.

  • Private placement: up to 571,428 shares @ $7.00/share → gross proceeds up to $4 M.

  • Aggregate Gross Proceeds: Up to $40 million (combined offering).

  • Placement Agent: Konik Capital Partners, LLC (division of T.R. Winston & Company, LLC) – exclusive agent.

  • Use of Proceeds:

  • Expansion of sales and marketing activities.
  • Working capital needs.
  • Research & development initiatives.
  • Funding strategic transactions (potential acquisitions or partnerships).

  • General corporate purposes.

  • Regulatory Filings: Offering made pursuant to an effective Form S‑3 shelf registration (File No. 333‑291516) declared effective on Dec 4 2025; prospectus supplement and base prospectus filed with the SEC.

  • Private Placement Specifics:

  • Targeted at Canadian purchasers only; no U.S. investors.
  • Expected closing on or prior to Dec 30 2025, subject to Toronto Stock Exchange conditional approval.

  • Shares subject to a lock‑up of four months plus one day from the private placement closing date.

  • Forward‑Looking Statements: The release contains typical forward‑looking language regarding use of proceeds, cash runway, and closing timelines; actual results may differ.

Notable Quotes

(No executive quotes were included in the release.)

Read the original news release →

More from PROFOUND MEDICAL CORP.

May 15, 2026 · 06:30

Profound Medical Corp.

Other May 14, 2026 · 07:00

TULSA-PRO's Conference Glow Hides a Long Road to Profitability

Other May 07, 2026 · 16:05

Humana coverage and surging procedure volumes push TULSA-PRO toward standard of care, but path to profitability still requires execution.

Earnings Mar 27, 2026 · 15:15

Profound talks up Tulsa procedure milestone in Texas

Production / Operations Mar 27, 2026 · 07:45

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure(TM) Milestone

Other Mar 13, 2026 · 10:30

CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure(TM) to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence

Other